Cyclacel Pharmaceuticals, Inc. - Common Stock (CYCC)
0.2360
-0.0119 (-4.80%)
NASDAQ · Last Trade: Jul 4th, 11:36 PM EDT
Detailed Quote
Previous Close
0.2479
Open
0.2479
Bid
0.2300
Ask
0.2350
Day's Range
0.2150 - 0.2500
52 Week Range
0.2150 - 39.84
Volume
2,594,625
Market Cap
84.10M
PE Ratio (TTM)
1.311
EPS (TTM)
0.2
Dividend & Yield
2.400 (1,016.95%)
1 Month Average Volume
4,059,665
Chart
About Cyclacel Pharmaceuticals, Inc. - Common Stock (CYCC)
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. The company leverages its proprietary drug development programs, which aim to address unmet medical needs in oncology, by targeting specific cancer cell cycle mechanisms and pathways. With a strong emphasis on research and development, Cyclacel is engaged in advancing its pipeline of therapeutic candidates towards clinical trials, seeking to bring new treatment options to patients with various types of cancer. Through its scientific expertise, the company strives to improve patient outcomes and contribute to the advancement of cancer care. Read More
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L876.
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series F Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors yielding gross proceeds of $3.0 million before deducting offering expenses. In connection with the offering, Cyclacel issued to each investor, a series A common stock purchase warrant to purchase 3,270,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) at an exercise price of $0.51 per share, series B common stock purchase warrant to purchase 3,270,000 shares of Common Stock at an exercise price of $0.60 per share and series C common stock purchase warrant to purchase 3,270,000 shares of Common Stock at an exercise price of $0.68 per share (collectively, the “Warrants”). The Warrants expire five years from the date of issuance. The offering closed on June 20, 2025.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
